Dosing Protocol
Typical Dose 8 mg
Range 1 - 12 mg
Loading Phase 1 mg × 28 days
Maintenance 8 mg weekly
Pharmacokinetics
Half-Life 6.0 days
Onset 1.0 days
Peak 3.0 days
Duration 7.0 days
Bioavailability 75%
Primary Route Subcutaneous
Administration
Routes Subcutaneous
Injection Sites Abdomen, Thigh, Deltoid
Needle Gauge 30-31G
Syringe Type Standard
Timing same day weekly
Special Instructions
Currently in Phase 3 clinical trials. Titrate slowly over 24-48 weeks to target dose.